Ethanolamine → HCID 178508137, compound

HRID 1813896Notes

Reaction equation

HRID 1813896 reaction equation
[C:1]1([S:7]([C:10]2[C:15](=[NH:16])[N:14]3[CH:17]=[CH:18][CH:19]=[CH:20][C:13]3=[N:12][C:11]=2SC)(=[O:9])=[O:8])[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[CH2:23]([CH2:25][NH2:26])[OH:24]>CN(C=O)C>[C:1]1([S:7]([C:10]2[C:15](=[NH:16])[N:14]3[CH:17]=[CH:18][CH:19]=[CH:20][C:13]3=[N:12][C:11]=2[NH:26][CH2:25][CH2:23][OH:24])(=[O:9])=[O:8])[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1

Participants

4

Reactant 2

HCID 700EthanolamineHCID 10286610HCID 10286610, compound

Product 1

HCID 178508137HCID 178508137, compoundYield 10%

Reagents, catalysts & solvents 1

HCID 6228DimethylformamideSolvent

Conditions

Temperature
55 °C

Procedure

To a one dram vial was added 20 mg (0.0604 mmol) of 3-(benzenesulfonyl)-2-methylsulfanyl-pyrido[1,2-a]pyrimidin-4-ylideneamine and 1.1 equivalents of ethanolamine in 750 ml of DMF. The vial was fitted with a TEFLON® lined cap and heated to 55° C. over night. The resulting product was then purified on a reverse phase preparative HPLC (XTerra™ MS C18 5.0 mM, MeOH/H2O as the eluent) to give 23 mg of the title compound as a brown solid; 10% yield.

Workup

  1. customlined cap
  2. customThe resulting product was then purified on a reverse phase preparative HPLC (XTerra™ MS C18 5.0 mM, MeOH/H2O as the eluent)

Sources & evidence

ORD record
ord-8663fc3d71e347adad3df0f4f7c549ec
Source dataset
uspto-grants-2005_04
Patent number
US06875771B2

Reaction notes

Loading…